Goldman Sachs’s Sonnet BioTherapeutics SONN Stock Holding History

Goldman Sachs’s Portfolio SONN Stock Details SONN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-55,134	Closed	-$253K	–	6789
2025 Q3	$253K	Buy	+55,134	New	+$245K	﹤0.01%	5846
2016 Q1	–	Hold	0	–	-$19K	–	7313
2015 Q4	–	Hold	0	–	–	–	6856

Other funds holding SONN

FAM

Formidable Asset Management Cincinnati, Ohio $629M AUM 15.56% 1-Year Est. Return

Goldman Sachs's SONN Position: Q4 2025 in Review

Goldman Sachs sold out of Sonnet BioTherapeutics (SONN) in Q4 2025, closing a stake of 55,134 shares — an estimated $253K sold.

Goldman Sachs first reported a position in SONN in Q3 2025 and held it in 1 quarter. The position peaked at $253K in Q3 2025. 1 fund tracked by Wall St. Rank holds SONN as of Q4 2025.

Goldman Sachs reported no remaining Sonnet BioTherapeutics position as of Q4 2025 after selling out during the quarter.
Goldman Sachs sold 55,134 Sonnet BioTherapeutics shares in Q4 2025, an estimated $253K.
Goldman Sachs first reported a position in Sonnet BioTherapeutics in Q3 2025 and held it in 1 quarter.
Goldman Sachs's Sonnet BioTherapeutics position peaked at $253K in Q3 2025.
1 fund tracked by Wall St. Rank held Sonnet BioTherapeutics as of Q4 2025.

Based on Goldman Sachs's 13F filing for Q4 2025, filed 10 Feb 2026.